217 related articles for article (PubMed ID: 28858382)
1. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment.
Charman C
Br J Dermatol; 2017 Oct; 177(4):1004-1005. PubMed ID: 28858382
[No Abstract] [Full Text] [Related]
2. Pimecrolimus: a review of its use in atopic dermatitis.
Wellington K; Noble S
Am J Clin Dermatol; 2004; 5(6):479-95. PubMed ID: 15663345
[TBL] [Abstract][Full Text] [Related]
3. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
Dattola A; Silvestri M; Bennardo L; Del Duca E; Longo C; Bianchi L; Nisticò S
Dermatol Ther; 2018 Nov; 31(6):e12728. PubMed ID: 30295379
[TBL] [Abstract][Full Text] [Related]
4. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
Qureshi AA; Fischer MA
Arch Dermatol; 2006 May; 142(5):633-7. PubMed ID: 16702502
[No Abstract] [Full Text] [Related]
5. How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema?
Wilkes SR; Nankervis H; Tavernier E; Maruani A; Williams HC
J Invest Dermatol; 2016 Oct; 136(10):1944-1949. PubMed ID: 27265005
[TBL] [Abstract][Full Text] [Related]
6. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids.
Kirsner RS; Heffernan MP; Antaya R
Acta Derm Venereol; 2010; 90(1):58-64. PubMed ID: 20107727
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence.
Kalavala M; Dohil MA
Am J Clin Dermatol; 2011 Feb; 12(1):15-24. PubMed ID: 21067248
[TBL] [Abstract][Full Text] [Related]
9. [Current aspects of the therapy with topical calcineurin inhibitors].
Enderlein E; Meller S; Rieker J; Ruzicka T; Homey B
Hautarzt; 2005 Oct; 56(10):937-41. PubMed ID: 16142499
[TBL] [Abstract][Full Text] [Related]
10. Multiple labial melanotic macules occurring after topical application of calcineurin inhibitors.
Shi VY; Joo JS; Sharon VR
Dermatol Online J; 2014 Aug; 20(8):. PubMed ID: 25148283
[TBL] [Abstract][Full Text] [Related]
11. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
12. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
13. Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.
Prucha H; Schnopp C; Akdis C; Lauener R; Wollenberg A; Ring J; Traidl-Hoffmann C
Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1507-16. PubMed ID: 23876065
[TBL] [Abstract][Full Text] [Related]
14. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D
J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on topical pimecrolimus in pediatric atopic dermatitis.
Yang LP; Curran MP
Am J Clin Dermatol; 2010; 11(4):295-8. PubMed ID: 20509720
[TBL] [Abstract][Full Text] [Related]
16. Itching for a solution.
Lapsley P
BMJ; 2005 Mar; 330(7490):522. PubMed ID: 15731120
[No Abstract] [Full Text] [Related]
17. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal.
Weidinger S; Baurecht H; Schmitt J
Br J Dermatol; 2017 Oct; 177(4):999-1003. PubMed ID: 28868633
[TBL] [Abstract][Full Text] [Related]
18. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial.
Bangert C; Strober BE; Cork M; Ortonne JP; Luger T; Bieber T; Ferguson A; Ecker RC; Kopp T; Weise-Riccardi S; Guettner A; Stingl G
Dermatology; 2011 Feb; 222(1):36-48. PubMed ID: 21150167
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
20. Macrolactam immunomodulators (tacrolimus and pimecrolimus): new horizons in the topical treatment of inflammatory skin diseases.
Grunwald MH; Ben Amitai D; Amichai B
J Dermatol; 2004 Aug; 31(8):592-602. PubMed ID: 15492431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
